US dermatology top boss moves to Danish biotech firm

Draupnir Bio, which landed DKK 225m from four venture funds last year, will soon get a new boss in the form of Andrew Hotchkiss, who has previously worked as the CEO of Dermira. Further, the company is upgrading its board with a former Abbvie and Amgen executive.

Draupnir Bio CSO Simon Glerup | Photo: Draupnir Bio / PR

Danish biotech company, which raised DKK 225m (USD 36.2m) in capital in 2019  from a series of European venture funds including Novo Seeds will be changing its CEO.

Co-founder, CEO and Chief Scientific Officer Simon Glerup leaves the company, which is developing a tablet against blood clots in the heart. Now, he will function as the CSO and board member of the firm, while Andrew Hotchkiss, who has previously worked for Eli Lilly-owned biotech firm Dermira, will take on the role of CEO, according to a Wednesday press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs